ClinicalTrials.gg
RecruitingNCT06577415Updated Mar 19, 2025

A Study of RAY1225 in Participants With Impaired Liver Function

A Phase 1 interventional study of RAY1225 in Hepatic Impairment, sponsored by Guangdong Raynovent Biotech Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-19.

Sponsored by Guangdong Raynovent Biotech Co., Ltd (part of Guangdong Zhongsheng Pharmaceutical Co., Ltd.) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year ago, but the record still lists the study as recruiting.
  • Started Aug 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The purpose of this study is to assess how fast RAY1225 gets into the blood stream and how long it takes the body to remove it in participants with impaired liver function compared to healthy participants.

02

Conditions studied

  • Hepatic Impairment
03

In context

Lead sponsor

Guangdong Raynovent Biotech Co., Ltd is the lead sponsor of 36 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant must be ≥ 18 to ≤ 75 years;
  2. ≥ 20 kg/m2 up to ≤ 32 kg/m2;
  3. Participants (including partners) must use reliable methods of during the study and until 6 months following the last dose of product;
  4. Signature of a dated Form (ICF) indicating that the participates has been informed of all the relevant aspects(including adverse events) of the trial prior to enrollment;
  5. ≥ 60 mL/min/1.73 m2;

    Participants with Normal Hepatic Function Only:

  6. Healthy males or females as determined by medical history, physical examination, and other screening procedures, with normal liver function;

    Participants with hepatic impairment only:

  7. Males or females with chronic mild and moderate liver impairment, assessed by scoring.

Exclusion criteria

Exclusion Criteria:

  1. Participants with an allergic disposition (multiple drug and food allergies) or who, as determined by the investigator, are likely to be allergic to the drug product or any component of the investigational drug product;
  2. > 450ms;
  3. Participants with serious infections, trauma, gastrointestinal surgery or other major surgical procedures within 4 weeks;
  4. Participates who donated blood or bleeding profusely (> 400 mL) in the 3 months;
  5. Pregnant or lactating women, or women of childbearing age with a positive pregnancy test;
  6. Smoking averaged more than 10 cigarettes per day in the 3 months prior to screening;
  7. Have a personal or family history of medullary thyroid carcinoma or have multiple endocrine neoplasia syndrome type 2;

    Participants with Normal Hepatic Function Only:

  8. Any history of hepatic impairment, or potential presence of liver function impairment by physical examination and laboratory examination at screening.

    Participants with Hepatic Impairment Only:

  9. Any history of clinically serious illness or disease or condition except for primary liver disease that the investigator believes may affect the results of the trial, including but not limited to a history of circulatory, endocrine, nervous, digestive, urinary, respiratory or hematological, immune, psychiatric, and metabolic disorders.
  10. Participants with drug-induced liver injury; history of liver transplantation; cirrhosis in combination with the following complications: including but not limited to liver failure, hepatic encephalopathy, hepatocellular carcinoma, esophageal bleeding from ruptured fundic varices.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Mild Hepatic Impairment

    Participants with mild hepatic impairment received single subcutaneous dose of 3 milligrams (mg) RAY1225.

    Drug: RAY1225

  • Experimental
    Moderate Hepatic Impairment

    Participants with moderate hepatic impairment received single subcutaneous dose of 3 mg RAY1225.

    Drug: RAY1225

  • Active comparator
    Normal Hepatic Function

    Participants with normal hepatic function received single subcutaneous dose of 3 mg RAY1225.

    Drug: RAY1225

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Area Under The Drug Concentration-Time Curve From Zero To Infinity (AUC[0-∞]) of RAY1225

    Pharmacokinetics (PK): Area Under The Drug Concentration-Time Curve From Zero To Infinity (AUC\[0-∞\]) of RAY1225.

    Time frame: DAY1~43

  2. PK: Maximum Observed Drug Concentration (Cmax) of RAY1225

    PK: Maximum Observed Drug Concentration (Cmax) of RAY1225

    Time frame: DAY1~43

Secondary outcomes

  1. Number of participants with drug-related adverse events as assessed by CTCAE v5.0

    Time frame: DAY1~43

07

Study locations

1 of 1 sites recruiting
  • Nanfang Hospital,South Medical Hospital
    Guangzhou, Guangdong, China
    Recruiting
    • Zhongyuan XU · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2024 (actual). Primary completion is estimated for Oct 2025, 14 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2024
First posted
Aug 29, 2024
StartActual
Aug 26, 2024
Primary completionEst.
Oct 31, 2025
CompletionEst.
Nov 15, 2025
Last update
Mar 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06577415
Responsible party
Sponsor
First posted
Aug 29, 2024
Start date
Aug 26, 2024
Primary completion
Oct 31, 2025 (estimated)
Completion
Nov 15, 2025 (estimated)
Last update
Mar 19, 2025

Study contacts

Zhongyuan XU
Contact
nfyygcp@126.com
020-62786845

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bilpatide

Start the discussion